select a format

Single User License
USD 2000 INR 0
Site License
USD 4000 INR 0
Corporate User License
USD 6000 INR 0


Request a quote
Request a Customized research
Request for Sample Report


Recent Viewed Reports

Why Ken Reasearch?


The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

Birch Pollen Allergy-Pipeline Review, H1 2015

Birch Pollen Allergy-Pipeline Review, H1 2015

  • Products Id :- GMDHC6081IDB
  • |
  • Pages: 49
  • |
  • January 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Birch Pollen Allergy-Pipeline Review, H1 2015


Global Markets Direct's, 'Birch Pollen Allergy-Pipeline Review, H1 2015', provides an overview of the Birch Pollen Allergy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Birch Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Birch Pollen Allergy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Birch Pollen Allergy and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Birch Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Birch Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Birch Pollen Allergy

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Birch Pollen Allergy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@]

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Birch Pollen Allergy Overview 6

Therapeutics Development 7

Pipeline Products for Birch Pollen Allergy-Overview 7

Pipeline Products for Birch Pollen Allergy-Comparative Analysis 8

Birch Pollen Allergy-Therapeutics under Development by Companies 9

Birch Pollen Allergy-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Birch Pollen Allergy-Products under Development by Companies 13

Birch Pollen Allergy-Companies Involved in Therapeutics Development 14

ALK-Abello A/S 14

Allergopharma Joachim Ganzer KG 15

Anergis SA 16

Biomay AG 17

Circassia Pharmaceuticals plc 18

HAL Allergy BV 19

Stallergenes S.A. 20

Birch Pollen Allergy-Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 27

ALK Birch Pollen Vaccine-Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

AllerT-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Birch-SPIRE-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

BM-31-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Drug for Birch Pollen Allergy-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

PL-102-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

rBet v1-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

rBet v1-FV-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Birch Pollen Allergy-Recent Pipeline Updates 38

Birch Pollen Allergy-Dormant Projects 40

Birch Pollen Allergy-Discontinued Products 41

Birch Pollen Allergy-Product Development Milestones 42

Featured News & Press Releases 42

Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT 42

Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT 42

Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT 43

Feb 27, 2014: Phase IIb Results of Anergis Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego 43

Oct 21, 2013: Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis's Birch Pollen Allergy Vaccine AllerT 43

Sep 10, 2013: Anergis Reports Positive Phase IIb Data for Birch Pollen Allergy Vaccine AllerT 44

Jan 23, 2013: Anergis Obtains US Patent For Lead Product AllerT 45

Nov 08, 2012: Long-Term Immunomodulation Induced By Anergis's COP Allergy Vaccine AllerT Extends To Fourth Year After Treatment 45

Nov 06, 2012: Anergis Starts European Phase IIb Clinical Trial With AllerT In Patients With Allergy To Birch Pollen 46

Jan 24, 2011: Anergis Obtains Core Technology Patent Protection in the US 46

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 49

Disclaimer 49

List of Tables

Number of Products under Development for Birch Pollen Allergy, H1 2015 7

Number of Products under Development for Birch Pollen Allergy-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Late Stage Development, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Comparative Analysis by Early Stage Development, H1 2015 12

Products under Development by Companies, H1 2015 13

Birch Pollen Allergy-Pipeline by ALK-Abello A/S, H1 2015 14

Birch Pollen Allergy-Pipeline by Allergopharma Joachim Ganzer KG, H1 2015 15

Birch Pollen Allergy-Pipeline by Anergis SA, H1 2015 16

Birch Pollen Allergy-Pipeline by Biomay AG, H1 2015 17

Birch Pollen Allergy-Pipeline by Circassia Pharmaceuticals plc, H1 2015 18

Birch Pollen Allergy-Pipeline by HAL Allergy BV, H1 2015 19

Birch Pollen Allergy-Pipeline by Stallergenes S.A., H1 2015 20

Assessment by Monotherapy Products, H1 2015 21

Number of Products by Stage and Target, H1 2015 22

Number of Products by Stage and Route of Administration, H1 2015 24

Number of Products by Stage and Molecule Type, H1 2015 26

Birch Pollen Allergy Therapeutics-Recent Pipeline Updates, H1 2015 38

Birch Pollen Allergy-Dormant Projects, H1 2015 40

Birch Pollen Allergy-Discontinued Products, H1 2015 41

List of Figures

Number of Products under Development for Birch Pollen Allergy, H1 2015 7

Number of Products under Development for Birch Pollen Allergy-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Early Stage Products, H1 2015 12

Assessment by Monotherapy Products, H1 2015 21

Number of Products by Top 10 Routes of Administration, H1 2015 23

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 24

Number of Products by Top 10 Molecule Types, H1 2015 25

Number of Products by Stage and Top 10 Molecule Types, H1 2015 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

ALK-Abello A/S

Allergopharma Joachim Ganzer KG

Anergis SA

Biomay AG

Circassia Pharmaceuticals plc

HAL Allergy BV

Stallergenes S.A.

Birch Pollen Allergy Therapeutic Products under Development, Key Players in Birch Pollen Allergy Therapeutics, Birch Pollen Allergy Pipeline Overview, Birch Pollen Allergy Pipeline, Birch Pollen Allergy Pipeline Assessment

Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@]